Brief: Moderna Exercises Option To License Proprietary Targeting Technology From Autolus

Autolus Therapeutics

12/10/2022 12:11

Oct 12 (Reuters) - Autolus Therapeutics PLC  AUTL.O :
    * MODERNA EXERCISES OPTION TO LICENSE PROPRIETARY TARGETING
TECHNOLOGY FROM AUTOLUS
    * AUTOLUS RECEIVES OPTION EXERCISE FEE, WITH POTENTIAL FOR
DEVELOPMENT MILESTONE PAYMENTS PLUS ROYALTIES
    * OPTION EXERCISED ON UNDISCLOSED IMMUNE-ONCOLOGY TARGET
FOLLOWING
EVALUATION PERIOD BY MODERNA -
    * OPTION EXERCISED ON UNDISCLOSED IMMUNE-ONCOLOGY TARGET
FOLLOWING
EVALUATION PERIOD BY MODERNA
    * AUTOLUS WOULD BE ENTITLED TO RECEIVE ROYALTIES ON NET
SALES OF
ALL PRODUCTS COMMERCIALIZED UNDER AGREEMENT.

Source text for Eikon:  ID:nGNX7ZMxP1 
Further company coverage:  AUTL.O